2024
Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and their influence on inflammatory biomarkers in pregnancy: Findings from the LIFECODES cohort
Siwakoti R, Harris S, Ferguson K, Hao W, Cantonwine D, Mukherjee B, McElrath T, Meeker J. Prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and their influence on inflammatory biomarkers in pregnancy: Findings from the LIFECODES cohort. Environment International 2024, 194: 109145. PMID: 39550829, DOI: 10.1016/j.envint.2024.109145.Peer-Reviewed Original ResearchC-reactive proteinNested case-control study of preterm birthCase-control study of preterm birthInflammatory biomarkersIL-10TNF-aInterquartile range increaseNested case-control studyStudy of preterm birthPre-pregnancy BMIQuantile-based g-computation approachIL-6Prenatal PFAS exposureInflammatory processPregnancy plasma samplesMeasurement of inflammatory biomarkersBirth outcomesLinear mixed modelsInverse associationRange increaseMaternal raceMaternal demographicsTNF-a levelsAdverse pregnancyAfrican Americans
2023
Adverse birth outcomes are associated with circulating matrix metalloproteinases among pregnant women in Puerto Rico
Kim C, Cathey A, Watkins D, Mukherjee B, Rosario-Pabón Z, Vélez-Vega C, Alshawabkeh A, Cordero J, Meeker J. Adverse birth outcomes are associated with circulating matrix metalloproteinases among pregnant women in Puerto Rico. Journal Of Reproductive Immunology 2023, 159: 103991. PMID: 37454540, PMCID: PMC10726844, DOI: 10.1016/j.jri.2023.103991.Peer-Reviewed Original ResearchConceptsBirth outcomesMatrix metalloproteinasesFetal sexPregnant womenFemale fetusesNewborn lengthVisit 3Associated with increased odds of preeclampsiaVisit 1Impact of matrix metalloproteinasesCustomized Luminex assayGestational diabetes mellitusOdds of preeclampsiaAdverse birth outcomesAssociated with increased oddsGestational ageHealthy pregnancyMale fetusesUterine remodelingLuminex assayLogistic regression modelsDiabetes mellitusStudy visitsInverse associationExtracellular matrix
2021
Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association
Khoja L, Weber RP, Group T, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology 2021, 164: 195-201. PMID: 34776242, PMCID: PMC9444325, DOI: 10.1016/j.ygyno.2021.10.088.Peer-Reviewed Original ResearchConceptsHistory of endometriosisOvarian cancer riskEPT useOvarian Cancer Association ConsortiumOvarian cancerInverse associationOdds ratioCancer riskCancer associationInvasive epithelial ovarian cancerHormone therapy useMenopausal hormone therapyEpithelial ovarian cancerCase-control studyConfidence intervalsSlight inverse associationWarrants further investigationHormone therapyTherapy usePooled analysisEndometriosisHysterectomyCancerTherapySelf-reported dataPer- and Polyfluoroalkyl Substances and Hormone Levels During the Menopausal Transition
Harlow S, Hood M, Ding N, Mukherjee B, Calafat A, Randolph J, Gold E, Park S. Per- and Polyfluoroalkyl Substances and Hormone Levels During the Menopausal Transition. The Journal Of Clinical Endocrinology & Metabolism 2021, 106: e4427-e4437. PMID: 34181018, PMCID: PMC8677593, DOI: 10.1210/clinem/dgab476.Peer-Reviewed Original ResearchConceptsMidlife womenSex hormone-binding globulinFollicle-stimulating hormoneInverse associationStudy of Women's HealthPositive associationMenopausal transitionBody mass indexReproductive ageWomen's HealthSignificant linear trendNo significant associationNulliparous womenLinear mixed modelsSmoking statusYears of ageMass indexHormone-binding globulinMenopausal statusLongitudinal serum concentrationsSignificant associationSerum PFAS concentrationsMidlifeWomenPolyfluoroalkyl substancesDepot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk
Phung M, Lee A, Wu A, Berchuck A, Cho K, Cramer D, Doherty J, Goodman M, Hanley G, Harris H, McLean K, Modugno F, Moysich K, Mukherjee B, Schildkraut J, Terry K, Titus L, Consortium O, Jordan S, Webb P, Consortium O, Pike M, Pearce C. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of ProgestinsDMPA Use Decreases Ovarian Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 927-935. PMID: 33619020, PMCID: PMC9281627, DOI: 10.1158/1055-9965.epi-20-1355.Peer-Reviewed Original ResearchConceptsOvarian cancer riskDepot medroxyprogesterone acetate useRisk of ovarian cancerDepot medroxyprogesterone acetateCancer riskOvarian cancerDecreased riskInverse associationRisk of invasive epithelial ovarian cancerRisk of ovarian cancer overallAssociated with decreased risk of ovarian cancerDecreased risk of ovarian cancerOvarian Cancer Association ConsortiumDecreased ovarian cancer riskSystematic reviewOvarian cancer overallInvasive epithelial ovarian cancerAssociated with decreased riskCombined oral contraceptive useInjectable progestin-only contraceptivesProgestin-only contraceptive useProgestin-releasing intrauterine deviceContraceptive useAssociated with ovarian cancerProgestin-only contraceptives
2020
Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies
Lee AW, Rosenzweig S, Wiensch A, Group T, Ramus SJ, Menon U, Gentry-Maharaj A, Ziogas A, Anton-Culver H, Whittemore AS, Sieh W, Rothstein JH, McGuire V, Wentzensen N, Bandera EV, Qin B, Terry KL, Cramer DW, Titus L, Schildkraut JM, Berchuck A, Goode EL, Kjaer SK, Jensen A, Jordan SJ, Ness RB, Modugno F, Moysich K, Thompson PJ, Goodman MT, Carney ME, Chang-Claude J, Rossing MA, Harris HR, Doherty JA, Risch HA, Khoja L, Alimujiang A, Phung MT, Brieger K, Mukherjee B, Pharoah PDP, Wu AH, Pike MC, Webb PM, Pearce CL. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal Of The National Cancer Institute 2020, 113: 301-308. PMID: 32766851, PMCID: PMC7936053, DOI: 10.1093/jnci/djaa099.Peer-Reviewed Original ResearchConceptsOvarian cancer riskInvasive epithelial ovarian cancerClear cell ovarian cancerIncomplete pregnanciesEpithelial ovarian cancerOvarian cancerOvarian Cancer Association ConsortiumCancer riskOdds ratioInvasive epithelial ovarian cancer casesEpithelial ovarian cancer casesHistotype-specific analysesHistotype-specific associationsOral contraceptive useInvasive ovarian cancerHistory of breastfeedingConfidence intervalsOvarian cancer casesCase-control studyOCAC studiesMajor histotypesPooled analysisInverse associationCancer casesComplete pregnancy
2017
Environmental phenol associations with ultrasound and delivery measures of fetal growth
Ferguson K, Meeker J, Cantonwine D, Mukherjee B, Pace G, Weller D, McElrath T. Environmental phenol associations with ultrasound and delivery measures of fetal growth. Environment International 2017, 112: 243-250. PMID: 29294443, PMCID: PMC5899051, DOI: 10.1016/j.envint.2017.12.011.Peer-Reviewed Original ResearchConceptsInverse associationBirth weight z-scoreWeight z-scoreZ-scoreFetal weightInterquartile range differenceFetal growthBirth weightUltrasound estimationUltrasound estimation of fetal weightEstimation of fetal weightLIFECODES birth cohortStandard deviation decreaseEstimated fetal weightBirth cohortOutcome measuresInvestigate sex differencesWomen's HospitalPregnant womenStudy populationStudy visitsDeviation decreaseDelivery measuresPregnancyAssociationSubclinical Changes in Maternal Thyroid Function Parameters in Pregnancy and Fetal Growth
Johns L, Ferguson K, Cantonwine D, Mukherjee B, Meeker J, McElrath T. Subclinical Changes in Maternal Thyroid Function Parameters in Pregnancy and Fetal Growth. The Journal Of Clinical Endocrinology & Metabolism 2017, 103: 1349-1358. PMID: 29293986, PMCID: PMC6018657, DOI: 10.1210/jc.2017-01698.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAsymptomatic DiseasesBirth WeightCase-Control StudiesFemaleFetal DevelopmentHumansInfant, NewbornPregnancyPregnancy ComplicationsPremature BirthProspective StudiesSocioeconomic FactorsThyroid DiseasesThyroid Function TestsThyroid GlandThyroid HormonesThyroxineUltrasonography, PrenatalYoung AdultConceptsBirth weight z-scoreOvert thyroid diseaseThyroid function parametersWeight z-scoreFetal growthThyroid diseaseInverse associationPregnant womenMeasurements of estimated fetal weightSubclinical changesIndices of fetal growthCase-control study of preterm birthStudy of preterm birthZ-scoreAbnormal fetal growthMaternal thyroid functionWeeks of gestationInfluence fetal growthZ-score decreaseThyroid-stimulating hormoneProspective birth cohortCase-control studyFunction parametersFetal weightPreterm birthUrinary BPA and Phthalate Metabolite Concentrations and Plasma Vitamin D Levels in Pregnant Women: A Repeated Measures Analysis
Johns L, Ferguson K, Cantonwine D, McElrath T, Mukherjee B, Meeker J. Urinary BPA and Phthalate Metabolite Concentrations and Plasma Vitamin D Levels in Pregnant Women: A Repeated Measures Analysis. Environmental Health Perspectives 2017, 125: 087026. PMID: 28934718, PMCID: PMC5783673, DOI: 10.1289/ehp1178.Peer-Reviewed Original ResearchConceptsCohort of pregnant womenMono-3-carboxypropyl phthalateVitamin D levelsPregnant womenD levelsNested case-control study of preterm birthMeasures of urinary phthalate metabolitesProspective cohort of pregnant womenOdds of vitamin D deficiencyCase-control study of preterm birthDi(2-ethylhexyl) phthalate metabolitesInverse associationStudy of preterm birthInterquartile rangePlasma vitamin D levelsCirculating total 25(OH)DNested case-control studyMetabolites of di(2-ethylhexyl) phthalateVitamin D deficiencyDi(2-ethylhexyl) phthalatePhthalate metabolite concentrationsUrinary phthalate metabolitesUrinary bisphenol AProspective birth cohortPreterm birth
2016
Urinary phthalate metabolite and bisphenol A associations with ultrasound and delivery indices of fetal growth
Ferguson K, Meeker J, Cantonwine D, Chen Y, Mukherjee B, McElrath T. Urinary phthalate metabolite and bisphenol A associations with ultrasound and delivery indices of fetal growth. Environment International 2016, 94: 531-537. PMID: 27320326, PMCID: PMC4980186, DOI: 10.1016/j.envint.2016.06.013.Peer-Reviewed Original ResearchConceptsActual fetal weightUrinary phthalate metabolitesPhthalate metabolitesFetal weightFetal growthDi-2-ethylhexyl phthalate metabolitesNon-anomalous singleton pregnanciesAssociated with decreased fetal growthConcentrations of phthalate metabolitesTime pointsExposure to di-2-ethylhexyl phthalateSingleton pregnanciesLongitudinal birth cohortFetal sexDi-2-ethylhexyl phthalateInterquartile range increaseCross-sectional associationsUltrasound scanPregnancyInverse associationMaternal exposureDelivery indexUrine samplesStandard deviation decreaseBirth cohort
2013
Associations between brominated flame retardants in house dust and hormone levels in men
Johnson P, Stapleton H, Mukherjee B, Hauser R, Meeker J. Associations between brominated flame retardants in house dust and hormone levels in men. The Science Of The Total Environment 2013, 445: 177-184. PMID: 23333513, PMCID: PMC3572297, DOI: 10.1016/j.scitotenv.2012.12.017.Peer-Reviewed Original ResearchConceptsBrominated flame retardantsSex hormone binding globulinIndoor dustHouse dustThyroid-stimulating hormoneExposure to contaminantsFollicle stimulating hormoneFlame retardantsBody mass indexHouse dust concentrationsFlame retardant concentrationUS infertility clinicHormone levelsPBDE congenersLuteinizing hormoneStimulating hormoneEndocrine disruptionAssociated with total T3Inverse associationCommercial mixtureDecaBDE concentrationsReproductive effectsSerum free T4Increased free androgen indexFree androgen index